Ritz; Jerome
Patent Applications and Registrations
Patent applications and USPTO patent grants for Ritz; Jerome.The latest application filed is for "multiple-variable il-2 dose regimen for treating immune disorders".
- Ritz; Jerome - Lincoln MA
| Patent | Date |
|---|---|
| Multiple-variable Il-2 Dose Regimen For Treating Immune Disorders App 20210077580 - Koreth; John ; et al. | 2021-03-18 |
| Multiple-variable IL-2 dose regimen for treating immune disorders Grant 10,806,773 - Koreth , et al. October 20, 2 | 2020-10-20 |
| Multiple-variable Il-2 Dose Regimen For Treating Immune Disorders App 20170348391 - Koreth; John ; et al. | 2017-12-07 |
| Methods to detect lineage-specific cells App 20060292599 - Ritz; Jerome ; et al. | 2006-12-28 |
| Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof App 20030017159 - Ritz, Jerome ; et al. | 2003-01-23 |
| Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells Grant 4,772,552 - Hercend , et al. September 20, 1 | 1988-09-20 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 